Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
148.63
-0.64 (-0.43%)
At close: Apr 17, 2026, 4:00 PM EDT
151.25
+2.62 (1.76%)
After-hours: Apr 17, 2026, 7:33 PM EDT
Revolution Medicines Employees
Revolution Medicines had 883 employees as of December 31, 2025. The number of employees increased by 349 or 65.36% compared to the previous year.
Employees
883
Change (1Y)
349
Growth (1Y)
65.36%
Revenue / Employee
n/a
Profits / Employee
-$1,281,202
Market Cap
31.26B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 883 | 349 | 65.36% |
| Dec 31, 2024 | 534 | 156 | 41.27% |
| Dec 31, 2023 | 378 | 132 | 53.66% |
| Dec 31, 2022 | 246 | 58 | 30.85% |
| Dec 31, 2021 | 188 | 63 | 50.40% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BeOne Medicines AG | 12,000 |
| BioNTech SE | 7,807 |
| Moderna | 4,700 |
| Genmab | 2,973 |
| Incyte | 2,844 |
| Alnylam Pharmaceuticals | 2,500 |
| argenx SE | 1,863 |
| Insmed | 1,664 |
RVMD News
- 3 hours ago - Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 12 hours ago - Top 2 Health Care Stocks That May Fall Off A Cliff In Q2 - Benzinga
- 2 days ago - This Pill May Help Pancreatic Cancer Patients Live Longer - Forbes
- 2 days ago - Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes - GlobeNewsWire
- 4 days ago - Revolution Medicines, Inc. Announces Proposed Offerings of Common Stock and Convertible Senior Notes - GlobeNewsWire
- 4 days ago - Revolution Medicines surges 38% as pancreatic cancer drug shows breakthrough - Invezz
- 4 days ago - Revolution Medicines Rallies After Phase 3 Pancreatic Cancer Trial Doubles Survival Versus Chemo - Benzinga
- 4 days ago - This Biotech Stock Soars 38%. Pancreatic Cancer Trial Was a Success. - Barrons